How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure?

Nephrology Dialysis Transplantation

Volumn 17, Issue 6, 2002, Pages 965-969

  Goldsmith, David ^a   MacGinley, Robert ^a   Smith, Andrew ^a   Covic, Adrian ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b CI Parhon Hospital   (Romania)

Author keywords

Arterial compliance; Arteriosclerosis; Cardiovascular mortality; Renal failure; Vascular function

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID; NITRIC ACID DERIVATIVE; PERINDOPRIL; RAPAMYCIN; SEVELAMER; STEROID;

ARTERY CALCIFICATION; BLOOD VESSEL COMPLIANCE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; EDITORIAL; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; PULSE PRESSURE; PULSE WAVE; RISK FACTOR; UREMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; PATHOPHYSIOLOGY; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RISK FACTORS; VASCULAR DISEASES;

EID: 0035991929     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.6.965     Document Type: Editorial

References (40)

1. Coronary artery disease in uremia-etiology, diagnosis and therapy
2. Explained and unexplained ischemic heart disease risk after renal transplantation
3. Controlling the epidemic of cardiovascular disease in chronic renal failure: What do we know? What do we need to learn? Where do we go from here?
4. The prognostic importance of left ventricular geometry in uremic cardiomyopathy
5. Ambulatory blood pressure monitoring in renal dialysis and transplant patients
6. Pulse pressure changes with six classes of antihypertensive agents in a randomised controlled trial
7. Drug treatment of isolated systolic hypertension
8. Pulse pressure, arterial stiffness and drug treatment of hypertension
9. Pulse pressure: A predictor of long term cardiovascular mortality in a French male population
10. Is pulse pressure useful in predicting risk in coronary heart disease? The Framingham heart study
11. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis
12. Wave travel and reflection in the arterial system
13. Cardiac and arterial interactions in end-stage renal disease
14. Alterations of arterial function in end-stage renal disease
15. Arterial calcifications, arterial stiffness and cardiovascular risk in end-stage renal disease
16. Impact of aortic stiffness attenuation on survival of patients in end-stage renal disease
17. Atherosclerosis and arteriosclerosis in chronic renal failure
18. Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms
19. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients
20. Asymmetric dimethyl-arginine, C-reactive protein and carotid intima-media thickness in end-stage renal disease
21. Stiffness of carotid artery wall material and blood pressure in humans: Application to antihypertensive therapy and stroke prevention
22. Aminoguanidine and aortic wall mechanics, structure and composition in aged rats
23. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys
24. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker
25. Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: Evidence for smooth muscle cell-mediated vascular calcification
26. Recent advances in multifactorial regulation of vascular calcification
27. Vascular calcification in long-term haemodialysis patients in a single unit: A retrospective analysis
28. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
29. Phosphate regulation of vascular smooth muscle cell calcification
30. Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium-based phosphate binders
31. Phosphate binders in uraemia: Pharmaco-dynamics, pharmacoeconomics, pharmacoethics
32. Arterial calcifications, arterial stiffness and cardiovascular risk in end-stage renal diseases
33. BMP-7 is an effective treatment for vascular calcification in chronic kidney disease
34. Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin
35. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption
36. Elastin calcification and its prevention with aluminum chloride pretreatment
37. Cyclosporin Associated hypertension-pathomechanisms and clinical consequences
38. Study of arterial and autonomic effects of cyclosporine in humans
39. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine
40. Cardiac and vascular abnormalities in renal transplant patients: Differential effects of cyclosporin and azathioprine